Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial

Antonio Avallone, Alfredo Budillon, Alfonso De Stefano et al.|Journal of Clinical Oncology|2024

Cited by 14